(JAGX) Jaguar Health, Inc. Business Model Canvas Research

Specialty pharmacies and distributors are central to Mytesi access because they handle prescription fulfillment, reimbursement checks, cold-chain-free shipping, and patient support. Jaguar Health, Inc. reported net product revenue of $13.8 million in 2025, and this channel matters because Mytesi sales depend on getting each prescription through payer approval and last-mile delivery.

• Support reimbursement approval
• Ship prescriptions to patients
• Drive Mytesi commercialization

Veterinary specialists and academic labs are key partners for Jaguar Health, Inc. They help test Canalevia, build trust with veterinarians, and speed adoption in animal health and rare-disease work.

• Support clinical development and research
• Drive vet awareness and use
• Help expand pipeline programs

Mytesi is Jaguar Health, Inc.’s approved prescription product and the main current revenue driver, so commercialization sits at the center of the business model. Sales efforts focus on prescribers, payer access, and patient support to keep starts and refills moving; in 2025, this remains the core operating priority for a company still built around a single branded asset.

• Approved Rx product
• Prescriber-led sales
• Access and support
• Main revenue engine

Jaguar Health, Inc. must manage raw materials, manufacturing, packaging, and release testing across its botanical supply chain, because quality control is critical when the active ingredient comes from plant sources. This work supports both human and animal products, including Mytesi and Canalevia-CA1.

That means tighter vendor checks, batch testing, and release sign-off to keep product quality consistent and protect regulatory compliance.

• Secure botanicals and packaging
• Test each batch before release
• Support human and animal lines

Jaguar Health, Inc.'s GI development expertise centers on crofelemer and diarrhea-focused drug work across oncology, orphan, and veterinary uses, with 3 main program paths that share the same core know-how. That reuse helps cut development friction, speed execution, and support a smaller team around one well-defined GI niche.

• Diarrhea-focused R&D core
• Oncology, orphan, veterinary use cases
• Shared know-how lowers friction

Jaguar Health, Inc.’s plant-derived formulation know-how sits at the core of its work with botanical drug components and the manufacturing steps that keep each batch consistent. In a business where source quality and formulation stability can make or break regulatory and commercial execution, this know-how is a key operational edge.

• Controls plant-based input quality
• Supports consistent batch formulation
• Helps protect product differentiation

Jaguar Health, Inc. targets ultra-rare GI diseases like congenital diarrheal disorders and short bowel syndrome, where U.S. short bowel syndrome with intestinal failure affects about 25,000–40,000 people and treatment options are thin. These orphan uses can qualify for faster regulatory paths and fit specialist prescriber networks, where small patient pools still support pricing power.

• High unmet need
• Orphan-drug pathway upside
• Specialist prescribing fit

Canalevia targets chemotherapy-induced and exercise-induced diarrhea in dogs, extending Jaguar Health, Inc.'s GI know-how into animal health. That gives Jaguar Health, Inc. a second commercial lane beyond human medicine and broadens its addressable market with a veterinary product built on the same intestinal-secretory control platform.

• Dog diarrhea treatment
• Veterinary GI expansion
• Second revenue lane

Jaguar Health, Inc. should treat rare-disease families as a core channel: about 300 million people live with rare diseases worldwide, and roughly 50% are children. In orphan care, patient and caregiver groups lift awareness, speed diagnosis, and help fill small trials, which is critical when many rare diseases still lack approved therapy.

• Patient groups drive awareness.

• Caregivers aid diagnosis and trial recruitment.

• Pediatric cases need family-led engagement.

Veterinary professional support is central to Jaguar Health, Inc.'s animal-health adoption: clinic staff drive diagnosis, treatment choice, and follow-up, so their trust directly shapes Canalevia use. Canalevia-CA1 is Jaguar Health, Inc.'s FDA-approved dog product, and that makes veterinarians the gatekeepers for uptake and repeat prescribing.

• Vet trust drives Canalevia adoption
• Clinic staff affect follow-up adherence
• FDA-approved dog product aids uptake

Hospital and oncology networks are Jaguar Health, Inc.’s main channel for oncology-related diarrhea care, because cancer clinics manage treatment side effects and also run clinical trial enrollment. In the U.S., the American Cancer Society projected about 2.0 million new cancer cases in 2025, which keeps these settings central for patient access and product use.

• Care site for side-effect management
• Supports trial recruitment
• Reaches a large 2025 cancer base

Jaguar Health, Inc. uses veterinary clinics as the main channel for Canalevia, because veterinarians diagnose, recommend treatment, and oversee use. That fits the animal-health model: the clinic is both the access point and the trusted decision-maker for prescription and supervised therapies.

Canalevia’s clinic-led route helps Jaguar Health reach dog owners through professional guidance rather than direct consumer push, which suits a vet-prescribed product.

• Veterinarians drive treatment decisions
• Clinical oversight supports safe use
• Channel matches animal-health sales

Adults and children with short bowel syndrome and intestinal failure are a core orphan group for Jaguar Health, Inc. In the U.S., short bowel syndrome affects about 10,000 to 20,000 people, and many need long-term support for chronic diarrhea, fluid loss, and nutrition. That high unmet need fits Jaguar Health, Inc.’s rare-disease strategy.

• About 10,000-20,000 U.S. patients
• Chronic, complex diarrhea burden
• Strong orphan-market fit

Canalevia targets dogs with chemotherapy-induced and exercise-induced diarrhea, so Jaguar Health, Inc. sells to veterinarians and pet owners who decide on treatment. This stretches Jaguar Health, Inc. into animal health, and the U.S. dog market is large: 65.1 million households owned dogs in the 2023-2024 APPA survey.

• Vet and owner make the purchase
• Canalevia treats two diarrhea types
• Animal health expands Jaguar Health, Inc.

For Jaguar Health, Inc., regulatory and legal costs are recurring because each approval, orphan-drug filing, and label expansion can trigger new FDA work and outside counsel spend; in FY2026, a standard U.S. drug application user fee is about $4.3 million, before internal filing and clinical support costs. IP protection adds more legal spend through patents, trademarks, and dispute defense, so this line stays fixed even when sales are thin.

• Approval and label filings drive cash burn.
• Orphan work adds recurring regulatory costs.
• IP defense needs steady legal spend.

Jaguar Health, Inc. General and administrative costs cover public-company overhead: management, finance, HR, investor relations, legal, and SEC reporting, plus headquarters and office support. These costs keep corporate operations running, but they do not create product revenue directly.

• Management and reporting support public listing duties.

• Headquarters and admin staff sit in this bucket.

• Investor relations and compliance add fixed overhead.

Jaguar Health, Inc. can use licensing deals to monetize platform drugs without funding all sales in-house. In pharma, royalties are often low-single-digit to mid-teen percentages of net sales, plus usage-based milestone payments, so these streams can add cash on top of product revenue.

• Licensing lowers launch costs
• Royalties scale with partner sales
• Milestones add non-dilutive cash

That matters if Jaguar Health, Inc. expands reach through partners while keeping its own commercial spend tight.

Jaguar Health, Inc. can earn milestone payments from partners when a program hits clinical, regulatory, or commercial checkpoints, so this is non-product income tied to pipeline progress. For a small biotech, these receipts can fund R&D without another equity raise, which matters when cash burn stays high.

• Linked to trial, FDA, or sales events
• Non-product cash for pipeline financing
• Depends on partner deal terms